Guess which ASX 200 healthcare share is jumping 7% on a guidance update

This healthcare share is performing better than expected in FY 2024.

| More on:
a doctor in white coat and stethoscope stands in front of a building holding an electronic device in his hands.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Fisher & Paykel Healthcare Corporation Ltd (ASX: FPH) share price is having a strong finish to the week.

In morning trade, the ASX 200 healthcare share is up 7% to $24.10.

Why is this ASX 200 healthcare share surging on Friday?

Investors have been scrambling to buy the company's shares this morning following the release of an update on its guidance for FY 2024.

As a reminder, the company was previously guiding to operating revenue of approximately NZ$1.7 billion and net profit after tax in the range of approximately NZ$250 million to NZ$260 million. This was based on a NZ:US exchange rate of 58 cents.

Assuming a NZ:US exchange rate of ~61 cents for the remainder of the financial year, the ASX 200 healthcare share expects to deliver full year operating revenue of approximately NZ$1.73 billion and underlying profit after tax (excluding any fair value changes) in the range of approximately NZ$260 million to NZ$265 million.

What's driving this?

Fisher & Paykel Healthcare's managing director and CEO, Lewis Gradon, revealed that strong demand in its Hospital products segment has continued during the second half. He said:

In the Hospital product group, there has been a continuation of solid demand for our hospital consumables across the product portfolio throughout the second half, which is towards the upper end of our expectations from November.

Also supporting its performance was demand for its Evora Full obstructive sleep apnoea (OSA) mask. He adds:

In OSA masks, we have continued to see strong performance from our Evora Full mask. We have received positive feedback on our revolutionary F&P Solo mask after the recent release in early markets, and we look forward to its introduction in more countries in the coming months.

Revaluations

Failing to hold back the ASX 200 healthcare share is news that it expects to lower the valuation of some of its properties. It notes that a scheduled valuation of properties in Auckland and Mexico are due to commence soon. Management isn't expecting an overly favourable outcome because of higher interest rates. It said:

In preliminary discussions we have been advised that the higher interest rate environment and current zoning status of our land in Karaka will likely have an adverse impact on the Karaka property valuation. Any reduction in the value of the Karaka land would be recognised as a non-cash accounting adjustment in the income statement and will impact our reported net profit after tax for the year. The quantum of any potential reduction in value is currently unknown, and our FY24 earnings guidance excludes this non-cash effect.

Fisher & Paykel Healthcare's shares are now up 19% over the last six months.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

a biomedical researcher sits at his desk with his hand on his chin, thinking and giving a small smile with a microscope next to him and an array of test tubes and beackers behind him on shelves in a well-lit bright office.
Healthcare Shares

Broker says this ASX 200 biotech stock is a top buy

Let's see what Bell Potter is saying about this biotech.

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why CSL shares are a buy today despite the looming Trump tariffs

A leading expert believes CSL shares are still trading for a bargain today. Here's why.

Read more »

A businesswoman pulls her glasses down in shock to look at the bad news on her computer.
Healthcare Shares

Why did the Telix share price just crash 16%?

Investors are sending the Telix share price plunging today. But why?

Read more »

Broker analysing the share price.
Healthcare Shares

Expert: 2 ASX healthcare stocks to avoid before reporting season

Not all healthcare stocks are created equal.

Read more »

A group of people in a corporate setting do a collective high five.
Healthcare Shares

Should I buy Pro Medicus or CSL shares ahead of earnings season?

The ASX healthcare sector may be currently undervalued.

Read more »

Overjoyed man celebrating success with yes gesture after getting some good news on mobile.
Healthcare Shares

Why Mesoblast shares can keep storming higher

More big returns could be on the way for buyers of this high risk stock according to Bell Potter.

Read more »

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »